Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Tumori|August 27, 2020
Interstitial pneumonitis in the COVID-19 era: a difficult differential diagnosis in patients with lung cancerChiara Catania, Valeria Stati, Gianluca SpitaleriFuture Oncology (London, England)|September 12, 2017
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinibTommaso De Pas, Laura Pala, Chiara Catania, et al.Clinical Lung Cancer|December 25, 2021
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literatureChiara Catania, Bharathi Muthusamy, Gianluca Spitaleri, et al.Patient Education and Counseling|September 20, 2011
A new informed consent form model for cancer patients: preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM)Stefania Gori, Maria Teresa Greco, Chiara Catania, et al.Nature Reviews. Clinical Oncology|June 2, 2009
Breast cancer and pregnancy: how safe is trastuzumab?Hatem A Azim, Fedro A Peccatori, Sarah J Liptrott, et al.Expert Opinion on Pharmacotherapy|June 7, 2026
Targeted therapies in thoracic neuroendocrine tumors: challenges and failures of tyrosine kinase inhibition in lung and thymic carcinoidsAlice Laffi, Chiara Catania, Martino De Pas, et al.Expert Review of Clinical Pharmacology|September 15, 2016
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the dataAntonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.Recenti Progressi in Medicina|April 20, 2016
[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances]Alessia Pochesci, Antonio Passaro, Chiara Catania, et al.Journal of Thoracic Disease|April 15, 2016
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?Antonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.The Annals of Pharmacotherapy|October 26, 2006
Erlotinib-induced breast cancer regressionChiara Catania, Tommaso Martino De Pas, Giuseppe Pelosi, et al.Pageof 8